HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody

This article was originally published here

This randomized, placebo-controlled, ascending dose study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of HFB30132A in 24 healthy volunteers. A total of three cohorts

The post HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody appeared first on Pharmaceutical Business review.